Quick answer: which aligns with your goal?
- Primary goal = reduce visceral abdominal fat (VAT), especially in HIV‑associated lipodystrophy: Tesamorelin has clinical trial evidence for VAT reduction in this population. It is a GHRH analogue dosed daily.
- General GH support intent (sleep, recovery, body composition claims) with softer evidence: Ipamorelin is a ghrelin receptor agonist (GHRP class). Human outcomes data for body composition are limited; use is typically off‑label/compounded.
- Australian access: Both are prescription‑only. Tesamorelin access is restricted and not indicated for general weight loss. Ipamorelin is an unapproved product often accessed via authorised prescribers or SAS pathways; compounding rules apply.
- Safety lens: Both can raise IGF‑1 via GH signalling. Tesamorelin may affect glucose tolerance and is monitored closely. Ipamorelin’s real‑world safety depends on source, dosing and supervision.
How they work: same axis, different switches
Growth hormone (GH) secretion is primarily controlled by hypothalamic growth hormone–releasing hormone (GHRH) and ghrelin, with somatostatin providing inhibitory tone. Tesamorelin and ipamorelin stimulate this axis at different receptors.
- Tesamorelin: A synthetic analogue of human GHRH that binds GHRH receptors on pituitary somatotrophs, increasing pulsatile GH release and downstream IGF‑1. It has a defined 2 mg subcutaneous daily dose in studies.
- Ipamorelin: A selective ghrelin receptor (GHSR‑1a) agonist from the GHRP family that prompts pituitary GH release. It’s often claimed to have minimal effects on prolactin/cortisol relative to older GHRPs. Half‑life is short; protocols vary.
Evidence and expected outcomes
Tesamorelin: where evidence is strongest
- VAT reduction in HIV‑associated lipodystrophy: Randomised trials show statistically significant decreases in visceral adipose tissue and waist circumference versus placebo, with IGF‑1 increases.
- Metabolic signals: Studies note changes in triglycerides and IGF‑1; careful screening for glucose intolerance is recommended.
- General obesity: Not approved for this use; evidence and indications are limited outside HIV‑related VAT.
Ipamorelin: what is and isn’t known
- Human outcomes: Direct, high‑quality trials on fat loss or muscle gain are limited. Claims often extrapolate from GH physiology or small studies.
- Use patterns: Commonly combined with a GHRH analogue (e.g., CJC‑1295) to leverage dual‑pathway signaling; reported goals include sleep quality, recovery and body composition support.
- Consistency: Outcomes may vary due to product source, dosing, timing, and lifestyle factors.
Safety, side effects and monitoring
- Shared considerations (GH/IGF‑1–related): Water retention, joint or muscle aches, tingling, headache, carpal tunnel‑like symptoms, changes in IGF‑1. Any new or worsening symptoms should be discussed with a clinician.
- Tesamorelin‑specific: Can increase IGF‑1 and may affect glucose tolerance; monitoring of fasting glucose/HbA1c and IGF‑1 is common. Hypersensitivity reactions have been reported. Indicated for HIV‑associated VAT, not general weight loss.
- Ipamorelin‑specific: As an unapproved product in Australia, safety depends on medical oversight and product quality. Protocols vary; labs may include IGF‑1 and metabolic panels at clinician discretion.
Dosing, timing and administration (overview)
- Tesamorelin: Studied dose is 2 mg subcutaneously once daily, typically into the abdomen with rotation of sites. Adherence and consistent timing matter; medical supervision is required.
- Ipamorelin: Protocols vary widely (e.g., 100–300 mcg once or multiple times daily, sometimes pre‑sleep, occasionally paired with CJC‑1295). Because half‑life is short, timing relative to meals/sleep and protocol design may influence response.
- Important: Dosing must be individualised by a prescribing clinician. Do not start, stop or change use without medical advice.
Who might consider which option?
- You have HIV‑associated lipodystrophy with excess VAT and meet clinical criteria: Tesamorelin is the evidence‑based, indicated option for reducing visceral fat in this specific setting under specialist care.
- You’re exploring general GH support claims (sleep, recovery, body composition) and your clinician considers it appropriate: Ipamorelin may be considered off‑label, recognising evidence gaps and the need for careful oversight and realistic expectations.
- You’re seeking weight‑loss medication for obesity: GLP‑1–based therapies (e.g., semaglutide, tirzepatide) have stronger evidence for weight loss than either peptide in the general population.
Legal access in Australia
- Prescription‑only: Both tesamorelin and ipamorelin require a valid prescription in Australia. Marketing to the public is restricted and clinical oversight is essential.
- Tesamorelin: Access is restricted; not indicated for general weight loss. Discuss availability, indication and monitoring with a specialist.
- Ipamorelin: Unapproved product status; access may occur via an Authorised Prescriber or Special Access Scheme. Compounding scrutiny and supply rules apply.
- Import risk: Personal importation can lead to seizure if rules are not met. Always verify lawful pathways before attempting to buy or import.
Tesamorelin legal status Ipamorelin legal status How to buy peptides lawfully
Alternatives and related comparisons
- CJC‑1295 (GHRH analogue): Sometimes compared or combined with ipamorelin. See CJC‑1295 vs Ipamorelin and CJC‑1295 DAC vs No DAC.
- Sermorelin (GHRH analogue): Often discussed for GH support. See CJC‑1295 vs Sermorelin and Ipamorelin vs Sermorelin. For tesamorelin context, see Tesamorelin vs Sermorelin.
- GLP‑1s for weight loss: For obesity and metabolic goals, compare Semaglutide vs Tirzepatide or visit the GLP‑1 Australia Guide.
Fast FAQs
Which is better for belly fat, tesamorelin or ipamorelin?
Tesamorelin has clinical evidence for reducing visceral abdominal fat in HIV‑associated lipodystrophy. It is not indicated for general weight loss. Ipamorelin evidence is limited for fat loss outcomes.
Can they be used together?
Some clinicians pair a GHRH analogue with a GHRP (e.g., CJC‑1295 + ipamorelin). Tesamorelin has a defined indication; combining interventions should only occur under medical supervision.
Will either increase IGF‑1?
Yes, via GH signalling. IGF‑1 monitoring is common. Your clinician will determine target ranges and frequency of labs.
What about glucose and diabetes risk?
Tesamorelin may affect glucose tolerance; screening and monitoring are recommended. Ipamorelin protocols should also consider metabolic risk factors.
How long until results?
Timelines depend on the goal. See tesamorelin results timeline and ipamorelin results timeline for expectation setting.
Get help choosing: free clinic connection
Use this form to request a call or email from a peptide‑aware clinic. They’ll explain eligibility, safer access pathways and what monitoring typically looks like in Australia.
Bottom line
If your intent is targeted reduction of visceral fat in HIV‑associated lipodystrophy, tesamorelin is the option with clinical evidence and defined dosing under specialist oversight. For broader GH support claims like sleep, recovery or general body composition, ipamorelin is commonly discussed but supported by limited outcomes data—appropriate use requires realistic expectations, lawful access and monitoring.